« Previous
Next »
Titles
- Abuse-deterrent formulations of opioids: effectiveness and value : final evidence report1
- Antiandrogen therapies for nonmetastatic castration-resistant prostate cancer: effectiveness and value : final evidence report1
- Biologic therapies for treatment of asthma associated with type 2 inflammation: effectiveness, value, and value-based price benchmarks : final evidence report1
- California's nurse practitioners: how scope of practice laws impact care1
- Chimeric antigen receptor T-cell therapy for B-cell cancers: effectiveness and value : final evidence report1
- Consideration of uncertainty in making benefit-risk determinations in medical device premarket approvals, de novo classifications, and humanitarian device exemptions: guidance for industry and Food and Drug Administration staff1
- Cost-effective screening and treatment of Hepatitis C1
- Disease-modifying therapies for relapsing-remitting and primary-progressive multiple sclerosis: effectiveness and value : final evidence report1
- Dupilumab and crisaborole for atopic dermatitis: effectiveness and value : final evidence report and meeting summary1
- Elagolix for treating endometriosis: final evidence report1
- Emicizumab for hemophilia A with inhibitors: effectiveness and value : final evidence report1
- Examining the cost effectiveness of teaching health centers1
- Extended-release opioid agonists and antagonist medications for addiction treatment (MAT) in patients with opioid use disorder: effectiveness and value : final evidence report1
- Factors to consider when making benefit-risk determinations in medical device premarket approval and de novo classifications: guidance for industry and Food and Drug Administration staff1
- Humanitarian device exemption (HDE) program: guidance for industry and Food and Drug Administration staff1
- Inotersen and patisiran for hereditary transthyretin amyloidosis: effectiveness and value : final evidence report1
- Modulator treatments for cystic fibrosis: effectiveness and value : final evidence report and meeting summary1
- Prophylaxis for hereditary angioedema with lanadelumab and C1 Inhibitors: effectiveness and value : final evidence report1
- Targeted immune modulators for rheumatoid arthritis: effectiveness & value : evidence report1
- Targeted immune modulators for rheumatoid arthritis: effectiveness and value : evidence report1